FRACTALKINE-ANTAGONISTS: A new treatment for inflammation and cardiac protection
Kancera is developing KAND567 against cardiovascular diseases
Great medical need but lack of innovation, until now.
The problem:
Inflammation causes half of the tissue damage in a heart attack
The solution:
KAND567 can slow down the acute inflammation
Next step
Clinical evaluation in patients
The future
From acute to chronic, from cardiovascular disease to cancer